Tuesday, September 30, 2008

Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology

THOUSAND OAKS, Calif., – Sep 30, 2008 – Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration’s independent meta-analysis of patient-level data from previously conducted, randomized, controlled, clinical studies evaluating erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen has submitted the executive summary to regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).

Read the rest of this entry

Posted in Press Releases

Monday, September 15, 2008

Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate

Additional Data From Separate Head-to-Head Trial Showed More Than 75 Percent of Patients Prefer the Administration and Frequency of Twice-Yearly Subcutaneous Injection Compared to Weekly Oral Pill

MONTREAL – Sept. 15, 2008 – Amgen (NASDAQ:AMGN) today announced full data results from a non-pivotal Phase 3 head-to-head, double-blind trial comparing bone mineral density (BMD) gains in postmenopausal women with low bone mass who transitioned from weekly oral alendronate (Fosamax(R)) to denosumab versus those who continued alendronate therapy. In addition, patient preference data from another non-pivotal head-to-head trial comparing denosumab to weekly oral alendronate were announced today at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Montreal.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Monday, September 15, 2008

Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen

STOCKHOLM, Sweden & THOUSAND OAKS, Calif. – Sept. 15, 2008 – Biovitrum AB (publ) (STO:BVT) and Amgen (NASDAQ:AMGN) announced today that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance(R) (palifermin) and Stemgen(R) (ancestim) from Amgen, and will also obtain from Amgen a worldwide exclusive license to Kineret(R) (anakinra) for its current approved indication. The agreement includes an inventory of the three products at an undisclosed value.

Read the rest of this entry

Posted in Press Releases, Product News

Thursday, September 11, 2008

Amgen to Present Important Clinical Trial Data at Two Key Congresses

New Denosumab Osteoporosis Data at ASBMR

Denosumab Oncology and Oncology Therapeutics Data at ESMO

THOUSAND OAKS, Calif. – Sept. 11, 2008 – Amgen (NASDAQ:AMGN) today announced it will present new data from osteoporosis studies of its investigational therapy, denosumab, at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting that will be held in Montreal, Sept. 12-16, 2008. Additionally, data from the denosumab oncology program and the oncology therapeutics portfolio of marketed and pipeline products will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress in Stockholm, Sweden, Sept. 12-16, 2008.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Thursday, September 04, 2008

Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers

THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa. – Sept. 4, 2008 – Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers (marketed as Remicade(R) (infliximab), Enbrel(R) (etanercept), Humira(R) (adalimumab) and Cimzia(R) (certolizumab pegol)).

Read the rest of this entry

Posted in Press Releases